Research and Markets has announced the addition of the "Alpha-1 Anti-Trypsin Deficiency Forecast in 9 Major Markets 2016-2026" report to their offering.
Alpha-1 Anti-Trypsin deficiency (AATD) is an inherited, rare condition that causes a complete or partial reduction in activity of Alpha-1 Anti-Trypsin (AAT) in the blood and lungs which leads to the deposit of excessive abnormal A1AT protein in liver cells.
This report provides the current prevalent population for Alpha-1 Anti-Trypsin across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Reasons to Buy:
Key Topics Covered:
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key comorbid conditions
8. Methodology for quantification of patient numbers
9. Top-line prevalence
10. Features of AATD patients
11. Abbreviations used in the report
12. Patient-Based Offering
13. Online Pricing Data and Platforms
For more information about this report visit http://www.researchandmarkets.com/research/c2d28r/alpha1
View source version on businesswire.com: http://www.businesswire.com/news/home/20160930005548/en/Business Wire
Last updated on: 30/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.